conivaptan has been researched along with enalaprilat anhydrous in 3 studies
| Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (enalaprilat anhydrous) | Trials (enalaprilat anhydrous) | Recent Studies (post-2010) (enalaprilat anhydrous) |
|---|---|---|---|---|---|
| 188 | 17 | 64 | 846 | 109 | 76 |
| Protein | Taxonomy | conivaptan (IC50) | enalaprilat anhydrous (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Mus musculus (house mouse) | 0.0115 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.2405 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0054 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0012 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.0036 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for conivaptan and enalaprilat anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for conivaptan and enalaprilat anhydrous
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |